renaschild / iStockphoto.com
A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept), preventing the roll-out of any copies in the US until 2029.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Enbrel, Sandoz, Amgen, Roche, Immunex, etanercept, rheumatoid arthritis, SCOTUS, Erelzi, Federal Circuit, Roche, patents, petition, biologic, validity